Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Por Bartlett, Nancy L.
Publicado no Hematology Am Soc Hematol Educ Program (2017)

Approaches to aggressive B-cell lymphomas in less fit patients

Por Bartlett, Nancy L.
Publicado no Hematology Am Soc Hematol Educ Program (2020)

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Por Mehta-Shah, Neha, Bartlett, Nancy L.
Publicado no Blood (2018)

(18)F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

Por Cashen, Amanda F., Dehdashti, Farrokh, Luo, Jingqin, Homb, Andrew, Siegel, Barry A., Bartlett, Nancy L.
Publicado em 2011

Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551

Por Bartlett, Nancy L., Johnson, Jeffrey L., Wagner-Johnston, Nina, Ratain, Mark J., Peterson, Bruce A.
Publicado no Cancer Chemother Pharmacol (2008)

High Incidence of Methotrexate Associated Renal Toxicity in Patients with Lymphoma: A Retrospective Analysis

Por May, Jori, Carson, Kenneth R., Butler, Sara, Liu, Weijian, Bartlett, Nancy L., Wagner-Johnston, Nina D.
Publicado em 2013

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Por Smith, Sonali M., Schöder, Heiko, Johnson, Jeffrey L., Jung, Sin-Ho, Bartlett, Nancy L., Cheson, Bruce D.
Publicado no Leuk Lymphoma (2013)

Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies

Por Forero-Torres, Andres, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L., Rosenblatt, Joseph D., Kennedy, Dana A., Younes, Anas
Publicado em 2012

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

Por Wildes, Tanya M., Farrington, Laura, Yeung, Cecilia, Harrington, Alexandra M., Foyil, Kelley V., Liu, Jingxia, Kreisel, Friederike, Bartlett, Nancy L., Fenske, Timothy S.
Publicado em 2014

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

Por Chen, Robert, Allibone, Suzanne, Bartlett, Nancy L, Brice, Pauline, Chen, Andy, Pose, Katrina, Rich, Lynn, Bonthapally, Vijay, Garfin, Phillip M, Fanale, Michelle
Publicado no Onco Targets Ther (2016)

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

Por Wagner-Johnston, Nina D., Link, Brian K., Byrtek, Michelle, Dawson, Keith L., Hainsworth, John, Flowers, Christopher R., Friedberg, Jonathan W., Bartlett, Nancy L.
Publicado no Blood (2015)

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Por Morrison, Vicki A., Jung, Sin-Ho, Johnson, Jeffrey, LaCasce, Ann, Blum, Kristie A., Bartlett, Nancy L., Pitcher, Brandelyn N., Cheson, Bruce D.
Publicado no Leuk Lymphoma (2014)

Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma

Por Carson, Kenneth R., Bartlett, Nancy L., McDonald, Jay R., Luo, Suhong, Zeringue, Angelique, Liu, Jingxia, Fu, Qiang, Chang, Su-Hsin, Colditz, Graham A.
Publicado em 2012

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

Por Leonard, John P., Jung, Sin-Ho, Johnson, Jeffrey, Pitcher, Brandelyn N., Bartlett, Nancy L., Blum, Kristie A., Czuczman, Myron, Giguere, Jeffrey K., Cheson, Bruce D.
Publicado no J Clin Oncol (2015)

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

Por Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
Publicado no Blood (2014)

Assessment of Cellular Proliferation in Tumors by PET Using (18)F-ISO-1

Por Dehdashti, Farrokh, Laforest, Richard, Gao, Feng, Shoghi, Kooresh I., Aft, Rebecca L., Nussenbaum, Brian, Kreisel, Friederike H., Bartlett, Nancy L., Cashen, Amanda, Wagner-Johnson, Nina, Mach, Robert H.
Publicado em 2013

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

Por Rosenbaum, Cara A., Jung, Sin-Ho, Pitcher, Brandelyn, Bartlett, Nancy L., Smith, Sonali M., Hsi, Eric, Wagner-Johnston, Nina, Thomas, Sachdev P., Leonard, John P., Cheson, Bruce D.
Publicado no Br J Haematol (2019)

Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter Study

Por Kahl, Brad S., Bartlett, Nancy L., Leonard, John P., Chen, Ling, Ganjoo, Kristen, Williams, Michael E., Czuczman, Myron S., Robinson, K. Sue, Joyce, Robin, van der Jagt, Richard H., Cheson, Bruce D.
Publicado em 2010

Interim FDG PET Imaging in Stage I/II Non-Bulky Hodgkin Lymphoma: Would using combined PET and CT criteria better predict response than each test alone?

Por Kostakoglu, Lale, Schöder, Heiko, Johnson, Jeffrey L., Hall, Nathan C., Schwartz, Lawrence H., Straus, David J., LaCasce, Ann S., Jung, Sin-Ho, Bartlett, Nancy L., Canellos, George P., Cheson, Bruce D.
Publicado no Leuk Lymphoma (2012)

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Por Lansigan, Frederick, Barak, Ian, Pitcher, Brandelyn, Jung, Sin‐Ho, Cheson, Bruce D., Czuczman, Myron, Martin, Peter, Hsi, Eric, Schöder, Heiko, Smith, Scott, Bartlett, Nancy L., Leonard, John P., Blum, Kristie A.
Publicado no Cancer Med (2018)